Clinical Trials Logo

Liver Regeneration clinical trials

View clinical trials related to Liver Regeneration.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05459883 Completed - Ischemia Clinical Trials

Splenic Artery Ligation and Portocaval Shunt in Small-for-size Syndrome

splen ligation
Start date: January 1, 2017
Phase:
Study type: Observational

Our study aimed at assessing the changes of portal vein pressure, portal vein flow and hepatic arterial flow (HAF) in liver remnants ≤ 30% of the standard liver volume by reducing portal vein overflow via ligation of the splenic artery.

NCT ID: NCT04565535 Completed - Liver Regeneration Clinical Trials

Effect of Novel Donor Lifestyle Optimisation Protocol on Liver Regeneration in Live Liver Donors

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Steatosis in case of live liver donors is on the rise and around 20- 40 % of prospective liver donors are estimated to have hepatic steatosis. Significant steatosis has been shown to be associated with inferior donor outcomes after liver transplant. Dietary and lifestyle modification has been shown to reduce steatosis and may help improve the donor outcomes after liver transplant. Donors will be randomized between two groups; one will be put under donor lifestyle optimization protocol and the other shall follow normal diet and lifestyle. Donors under optimization protocol would undergo diet modification in the form of healthy, low fat, high protein diet along with exercise for 2 weeks prior to the expected date of surgery. Investigations including liver volumetric assessment, LFT's , lipid profile , Fibroscan shall be done prior to initiation of the diet and then following completion of the 2 weeks of lifestyle modification before surgery. The intraoperative parameters including intraoperative blood loss shall be assessed and a liver biopsy will be taken intraoperatively to assess for steatosis and liver regeneration markers including CK7 and Ki 67 will be assessed. Following surgery, the liver regeneration in donor shall be assessed by doing a liver volumetry by Computed Tomography (CT) at POD7. Post surgery, the donor shall undergo daily LFT's, PT-INR and the time to its normalization and serum bilirubin shall be assessed. Markers of liver regeneration shall also be assessed initially a day before surgery and then at POD 1, 3 and 7.

NCT ID: NCT03213314 Completed - Surgery Clinical Trials

HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies

Hepatica
Start date: September 7, 2017
Phase: N/A
Study type: Interventional

This observational clinical cohort study aims to evaluate the clinical utility of LiverMultiScan in quantifying liver health prior to liver resection or TACE. The results will enable further developments in scanning protocols and software, and clearly define the relevance of applying this technology as part of the pre-operative assessment of the patient being considered for liver resection or TACE.

NCT ID: NCT02945059 Completed - Liver Regeneration Clinical Trials

Reversible Portal Vein Embolization Before Major Hepatectomy

EMBORES
Start date: January 15, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to prospectively evaluate the tolerance and efficiency of a new technique of preoperative selective portal vein embolization (PVE) in patients requiring major hepatic resection.

NCT ID: NCT00957619 Completed - Liver Regeneration Clinical Trials

Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)

Start date: March 2006
Phase: Phase 4
Study type: Interventional

The investigators hypothecate that pentoxyfilline increase significantly the liver regeneration and reduces significantly ischemia and reperfusion (I/R) injury in major liver using aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as marker of I/R injury.